TD Asset Management
CLYM

TD Asset Management’s Climb Bio CLYM Stock Holding History

TD Asset Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.71M Buy
250,102
+3,902
+2% +$22.5K ﹤0.01% 1002
2025
Q4 		$985K Buy
246,200
+156,800
+175% +$377K ﹤0.01% 1099
2025
Q3 		$180K Hold
89,400
– – ﹤0.01% 1227
2025
Q2 		$111K Hold
89,400
– – ﹤0.01% 1186
2025
Q1 		$109K Hold
89,400
– – ﹤0.01% 1207
2024
Q4 		$161K Hold
89,400
– – ﹤0.01% 1232
2024
Q3 		$445K Buy
+89,400
New +$632K ﹤0.01% 1312

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

TD Asset Management's CLYM Position: Q1 2026 in Review

TD Asset Management increased its Climb Bio (CLYM) stake by 1.6% in Q1 2026, buying an estimated $22.5K and bringing the position to 250,102 shares worth $1.71M. The position accounts for ﹤0.01% of the portfolio, ranked #1002.

TD Asset Management first reported a position in CLYM in Q3 2024 and has held it in 7 quarters since. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • TD Asset Management held 250,102 shares of Climb Bio worth $1.71M as of Q1 2026.
  • TD Asset Management bought 3,902 Climb Bio shares in Q1 2026, an estimated $22.5K.
  • Climb Bio made up ﹤0.01% of TD Asset Management's portfolio in Q1 2026, its #1002 holding.
  • TD Asset Management first reported a position in Climb Bio in Q3 2024 and has held it in 7 quarters since.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.